# Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

> **NCT01706666** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 3 (actual)

## Conditions studied

- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** lenalidomide
- **OTHER:** laboratory biomarker analysis
- **DRUG:** dexamethasone
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01706666
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-07
- **Primary completion:** 2014-07-10
- **Final completion:** 2016-05-17
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706666, "Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01706666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*